Net sales were TSEK 12,475 (8,598), +45%, cleared for currency effects +57%.
The loss after tax was TSEK 25,300 (21,677).
The loss per share was SEK 0.06 (0.10).
The cash flow from current operations was negative in the amount of TSEK 20,824 (12,548).
The gross margin was 63.0% (68.5%).
Electrode sales volume increased by 67% and was 28,634 (17,132) units. Repeat sales of electrodes to existing customers increased by 48%.
The full year in figures
Net sales were TSEK 40,461 (29,705), +36%, cleared for currency effects +43%.
The loss after tax was TSEK 87,063 (65,579).
The loss per share was SEK 0.24 (0.37).
The cash flow from current operations was negative in the amount of TSEK 84,578 (57,383).
The gross margin was 67.0% (71.0%).
Electrode sales volume increased by 38% and was 86,180 (62,210) units. Repeat sales of electrodes to existing customers increased by 35%.
Important events during the quarter
Overall sales increased by 45% (+57%, before currency effects). Sales in Germany within the skin cancer segment increased by 13%(19% in local currency). Sales in the US skin cancer market increased by 84% (106% in local currency) while the sales within the skin barrier segment increased by 294%.
The gross margin was in the quarter negatively affected by the currency development (negative impact of over 3%), first delivery of product to Castle Biosciences for clinical studies, increased price on gold and continued investments to ramp up production.
SciBase and Castle Biosciences expanded its collaboration and license agreement and entered into a loan agreement.
The Board of SciBase resolved to carry out a rights issue of approximately SEK 83m and decided on an offer to convert outstanding TO2 warrants into shares.
SciBase announced the expansion of its patent portfolio.
A Nomination Committee has been appointed for SciBase Holding’s Annual General Meeting in 2026.
An EGM was held on December 5, 2025.
Important events after the end of the period
SciBase announced the outcome of the offer to repurchase outstanding warrants of series TO 2. In total, 83.9% of the TO2 holders accepted the offer.
SciBase announced the outcome of the performed rights issue, where the issue was subscribed to 96.4% and provides the company with approximately SEK 80 million before issue costs.
A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns.
A recalculation of the terms for the remaining TO 2 warrants has been carried out after the completion of the rights issue.
Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma.
SciBase receives approval by FDA for extended labelling in the US.
Financial overview
Oct 1 - Dec 31
Jan 1 - Dec 31
THE GROUP
2025
2024*
2025
2024*
Net sales, SEK ths
12 475
8 598
40 461
29 705
Gross margin, %
63,0%
68,5%
67,0%
71,0%
Equity/Asset ratio, %
12,8%
59,4%
12,8%
59,4%
Net indebtness, multiple
6,84
0,68
6,84
0,68
Cash equivalents, SEK ths
22 604
11 245
22 604
11 245
Cashflow from operating activities, SEK ths
-20 824
-12 548
-84 579
-57 383
Earnings per share (before and after dilution), SEK
-0,06
-0,10
-0,24
-0,37
Shareholder's equity per share, SEK
0,02
0,17
0,02
0,21
Average number of shares, 000'
414 183
219 538
360 357
177 994
Number of shares at closing of period, 000'
414 183
219 538
414 183
219 538
Share price at end of period, SEK
0,29
0,41
0,29
0,41
Number of sold electrodes, pieces
28 634
17 132
86 180
62 210
Average number of employees
43
30
37
28
*for information around restatement see page 7 of pdf report
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on March 13, 2026.
This interim report report has not been subject to review by the Company’s auditors
Contact person:
Michael Colérus, CFO, +46 70 341 34 72
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ)
About SciBase and Nevisense SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
STOCKHOLM, Sweden - March 10, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, is pleased to announce the publication of a pivotal study in the leading journal Contact Dermatitis. The study, titled "Assessing Skin Barrier Integrity: A Comparative Study Using Transepidermal Water Loss, Electrical Impedance Spectroscopy and Corneometry," confirms that Nevisense Electrical Impedance Spectroscopy (EIS) is a robust and effective method for studying skin barrier integrity. The research compared Nevisense EIS technology against traditional metrics like Transepidermal Water Loss (TEWL) and Corneometry, evaluating their ability to detect barrier disruption in human in vivo models.
Key Scientific findings from the study:
Higher Sensitivity: EIS captured early, and subtle structural changes not detected by TEWL measurement, highlighting its value for quantifying skin barrier impairment and complementing established methods.
Early Biomarker Potential: The authors note that EIS is dependent on cell cohesion and lipid composition, whereas TEWL reflects water flux across the epidermis. Taken together, these findings highlight the potential of EIS to serve as a sensitive complementary method for barrier assessment and a potential early biomarker for skin barrier damage
"This study further validates EIS and Nevisense as a powerful tool for assessing skin barrier impairment," said Pia Renaudin, CEO of SciBase. "By offering a robust complement to traditional methods, Nevisense enables researchers and product developers to directly monitor skin barrier integrity and gain deeper insight into the skin's structural condition."
The article recently published in Contact Dermatitis Volume 94, Issue 4, April 2026, Pages 317-433 can be found here: https://onlinelibrary.wiley.com/doi/epdf/10.1111/cod.70080
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ)
Tel: +46 8 588 68 570
Email: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
STOCKHOLM, Sweden - March 5, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, , announced that Stephen D. Hess, MD, PhD, FAAD, has published a clinical article highlighting his real-world experience integrating Nevisense into routine melanoma detection. The article was published in The Dermatologist, a leading U.S. clinical dermatology journal.
In the publication, Dr. Hess outlines how Nevisense provides objective data to complement visual examination and dermoscopy when evaluating atypical pigmented lesions, and that Nevisense adds objective risk stratification in cases that are clinically challenging.
"In everyday practice, many pigmented lesions fall into a diagnostic gray zone," said Dr. Hess. "Nevisense adds objective, real-time information beneath the skin's surface, enhancing clinical judgment and supporting more accurate biopsy decisions."
"As melanoma incidence continues to rise, clinicians need reliable technology that provides actionable data," said Pia Renaudin, CEO of SciBase. "Dr. Hess's publication in The Dermatologist highlights the growing importance of objective technologies like Nevisense in advancing melanoma detection and improving patient outcomes."
The article can be found here: https://www.hmpgloballearningnetwork.com/site/thederm/practice-advances/precision-under-surface-electrical-impedance-spectroscopy-pigmented
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ)
Tel: +46 8 588 68 570
Email: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
STOCKHOLM, Sweden - March 2, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, today announced that it has received approval by FDA for its supplement to extend the labelling to include other healthcare professionals and not only dermatologists to perform the Nevisense procedure. Previously, the labelling only specified dermatologists as users but now it also includes healthcare professionals such as physician assistants and medical assistants working at dermatology clinics. A dermatologist still needs to initiate the test, but the actual measurement can now be performed by other healthcare professionals. This means that Nevisense now much easier can be integrated into a clinic's workflow thus potentially expanding SciBase customer utilization and easier access for patients.
"This is an important extension of our labelling as it makes it easier to integrate EIS and Nevisense into a clinic's workflow and becoming a part of the melanoma decision pathway. It also means that labs that perform tests now can include Nevisense in their offering. The expanded labelling and the recently published NCCN guidelines together with our ongoing reimbursement work gives me confidence regarding our US potential and growth," said Pia Renaudin CEO of SciBase.
DNB Carnegie Investment Bank AB (publ)
Tel: +46 8 588 68 570
E-mail: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
STOCKHOLM, Sweden - February 19, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, today announced that Nevisense (EIS) is included in the US National Comprehensive Cancer Network(NCCN) Clinical Practice Guidelines in Oncology formelanoma. The guidelines refer to EIS as a diagnostic support technology to aid in the detection of melanoma.
NCCN develops the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), which are recognized as the standard for clinical policy and patient care in oncology.
"The inclusion of Nevisense (electrical impedance spectroscopy) in the NCCN Guidelines underscores the importance of objective technologies in melanoma detection," said Dr. Alexander Meves, MD, dermatologist, professor at the Mayo Clinic College of Medicine. Dr. Alexander Meves added, "Guideline inclusion helps clinicians understand how technologies like Nevisense fit into established clinical strategies focused on earlier detection."
"Including electrical impedance spectroscopy in these guidelines reflects the ongoing need in melanoma detection to incorporate objective data that improves clinical judgment," said Dr. Darrell Rigel, MD, Clinical Professor of Dermatology at the New York University (NYU), and Past President of the American Academy of Dermatology. "While visual assessment and dermoscopy have long been shown to improve melanoma detection rates, our published clinical research demonstrates that adding Nevisense (EIS) provides a further statistically significant and clinically meaningful improvement."
"As melanoma incidence continues to rise, the need for earlier and more accurate assessment has never been greater," said Pia Renaudin CEO of SciBase. "NCCN Guidelines highlights the critical role of advanced, non-invasive, point-of-care technologies like Nevisense in helping clinicians detect melanoma earlier and improve outcomes for patients."
DNB Carnegie Investment Bank AB (publ)
Tel: +46 8 588 68 570
E-mail: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
STOCKHOLM, Sweden - February 17, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, announces that results from a new study will be presented in an oral presentation at the AAAAI conference in Philadelphia February 27 - March 2.
The study from Icahn school of Medicine of Mount Sinai in New York was conducted on newborns who have a first-degree relative affected by atopic disease - meaning they had an increased risk of developing atopic dermatitis.
The study included 19 infants, among whom Nevisense successfully identified those who later developed atopic dermatitis (AD). Within the first year of life, eight of the nineteen infants developed AD, and their Nevisense scores at birth were significantly higher.
Conclusion from the study was "Higher EIS scores, suggestive of impaired skin barrier, within the first week of life were significantly associated with development of AD in the first year of life."
"These are very promising results, demonstrating the potential of Nevisense to predict atopic dermatitis. The findings are especially interesting, as we are simultaneously conducting larger studies on predicting atopic dermatitis in children", said Pia Renaudin, CEO of SciBase.
The abstract for the oral presentation at AAAAI can be found here: Assessing the Skin Barrier Using Electrical Impedance Spectroscopy in Newborns to Predict Development of Atopic Dermatitis - Journal of Allergy and Clinical Immunology.
DNB Carnegie Investment Bank AB (publ)
Tel: +46 8 588 68 570
E-mail: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles the holder to subscribe for and the subscription price shall be recalculated following rights issues. Accordingly, SciBase Holding AB (the "Company" or "SciBase") has carried out a recalculation of warrants of series T0 2 due to the rights issue of shares that the board of directors resolved upon on 29 December 2025 (the "Rights Issue"). Following the completed recalculation, SciBase can announce that the number of shares that each warrant of series TO 2 entitles to subscribe for and the subscription price per share has changed in accordance with the following. Following the recalculation, one (1) warrant of series TO 2 entitles the holder to subscribe for 1.09 shares at a subscription price of SEK 0.38 per share, in accordance with the previously communicated terms and conditions for the warrants. Furthermore, the last day of trading in BTA issued within the framework of the Rights Issue has been changed to 9 February 2026.
Each warrant of series TO 2 entitles the holder to subscribe for 1.09 new shares in the Company during the period from and including on 3 April 2029, until and including 17 April 2029. The subscription price for subscription of shares with the support of warrants of series TO 2 corresponds to SEK 0.38 per share.
On 9 January 2026, SciBase announced the outcome of the repurchase offer regarding all warrants of series TO 2, which the board of directors resolved upon on 7 November 2025 (the "TO 2 Offer"). The outcome showed that holders of a total of 418,150 ,952 warrants of series TO 2 accepted the TO 2 Offer, corresponding to approximately 83.9 percent of all outstanding warrants of series TO 2. As a result of the TO 2 Offer, the total number of outstanding warrants of series TO 2 amounts to 80,383,883. Following the recalculation of the terms and conditions for the warrants of series TO 2, the Company may thus receive approximately SEK 33.3 million upon full exercise of all warrants of series TO 2. Upon full exercise, the Company's share capital will increase by SEK 4,380,921.60 through the issuance of a total of 87,618,432 new shares.
The terms and conditions for the warrants, including potential adjustments due to future share issues, are available on the Company's website.
Furthermore, the last day of trading in BTA issued in the Rights Issue has been changed to 9 February 2026. Conversion of BTA to shares will thus be carried out on 16 February 2026. The shares issued in the TO 2 Offer will be delivered in connection with the conversion of BTA to shares, i.e. on 16 February 2026.
The information was submitted for publication, through the agency of the contact person set out above, on February 6, 2026 at 08.00 CET.
Certified Advisor (CA):
DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]
About SciBase:
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the final outcome of the rights issue of shares resolved by the Company on 29 December 2025 (the "Rights Issue"). The Rights Issue has been subscribed to 96.4 percent, of which approximately 61.3 percent has been subscribed for with the support of subscription rights and approximately 35.1 percent without the support of subscription rights. Through the Rights Issue, the Company will receive approximately 79.9 MSEK before deduction of transaction costs. Furthermore, the Board of Directors of the Company has today, pursuant to the authorisation granted by the extraordinary general meeting held on 5 December 2025, resolved on a set-off issue of 209,075,476 shares at a subscription price of SEK 0.20 per share (which corresponds to the subscription price in the Rights Issue) (the "Set-off Issue"). Payment for the shares in the Set-off Issue is made through set-off of receivables that arose in connection with holders of warrants of series TO 2 accepting the offer to repurchase warrants of series TO 2 announced by the Company through a press release on 7 November 2025 (the "TO 2 Offer"). All shares in the Set-off Issue have been subscribed for and allotted.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT BE DONE WITHOUT APPLICATION OF EXEMPTIONS FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.
Outcome of the Rights Issue
The subscription period for the Rights Issue ended on 26 January 2026. The final outcome shows that the Rights Issue has been subscribed to 96.4 percent, of which approximately 61.3 percent has been subscribed for with the support of subscription rights and approximately 35.1 percent without the support of subscription rights.The subscription price in the Rights Issue amounted to SEK 0.20 per share and the Company will thereby receive approximately 79.9 MSEK before deduction of transaction costs of approximately SEK 3.4 million.
Allotment of shares subscribed for without subscription rights
Allotment of shares subscribed for without the support of subscription rights in the Rights Issue will be made in accordance with the principles set out in the information document prepared and published by the Company on 9 January 2026 in connection with the Rights Issue. Notification of allotment of shares subscribed for without the support of subscription rights will be sent via contract note to those who have been allotted such shares, and payment for such shares shall be made in cash in accordance with the instructions in the contract note. Shareholders with nominee-registered holdings will receive notification of allotment in accordance with the procedures of the respective nominee.
Set-off Issue regarding the TO 2 Offer
On 7 November 2025, the Company announced that the Board of Directors had resolved on the TO 2 Offer. In the TO 2 Offer, two (2) warrants of series TO 2 entitled the holder to one (1) new share in the Company. The acceptance period for the TO 2 Offer commenced on 8 December 2025 and ended on 8 January 2026. The TO 2 Offer has been accepted by holders of a total of 418,150,952 warrants of series TO 2, corresponding to approximately 83.9 percent of all outstanding warrants of series TO 2. Following the TO 2 Offer, the number of outstanding warrants of series TO 2 will amount to 80,383,883.
As previously communicated, subscription of shares in accordance with the TO 2 Offer shall in practice be made through subscription of shares in a directed set-off issue of new shares to the holders of warrants of series TO 2 that have accepted the TO 2 Offer. The Board of Directors of the Company has thus today, pursuant to the authorisation granted by the extraordinary general meeting held on 5 December 2025, resolved on the Set-off Issue. All shares in the Set-off Issue have been subscribed for and allotted.
The reason for the deviation from the shareholders' preferential rights is that the Company wishes to set off debt against new shares in the Company in accordance with the terms of the TO 2 Offer.
Payment for the shares in the Set-off Issue is made through set-off of receivables that arose in connection with the closing of the acceptance period for the TO 2 Offer. The subscription price amounts to SEK 0.20 per share (which corresponds to the subscription price in the Rights Issue). Prior to the resolution on the Set-off Issue, the Board of Directors has placed great emphasis on ensuring that the subscription price should be market-based in relation to the prevailing share price. The subscription price has been determined by the Board of Directors, in consultation with the Company's financial advisors, following arm's length negotiations with the investors, whereby the Board of Directors has considered several factors such as market conditions, the Company's financing needs and alternative cost for other financing, as well as assessed market interest for an investment in the Company. The Board of Directors' assessment is therefore that the subscription price in the Set-off Issue is market-based and thus reflects prevailing market conditions and demand from investors.
Number of shares and share capital
Through the Rights Issue, the number of shares increases by 399,271,881 and through the Set-off Issue, the number of shares increases by 209,075,476. In total, the number of shares increases by 608,347,357, from 414,182,643 to 1,022,530,000. Through the Rights Issue, the share capital increases by 19,963,594.05 SEK and through the Set-off Issue the share capital increases by 10,453,773.80 SEK. In total, the share capital increases by 30 417 367,85 SEK, from SEK 20,709,132.15 to 51 126 500,00 SEK. The total dilution effect thus amounts to approximately 59.5 percent (calculated on the number of shares in the Company following the outcome of the Rights Issue and the Set-off Issue).
Trading in BTAs and the new shares in the Rights Issue and the Set-off Issue
The last day of trading in BTAs in the Rights Issue on Nasdaq First North Growth Market is expected to be on or around 13 February 2026. Trading in the new shares issued through the Rights Issue and the Set-off Issue is expected to commence on Nasdaq First North Growth Market on or around 19 February 2026.
Advisors
SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisors and Advokatfirman Schjødt as legal advisor in connection with the Rights Issue and the TO2 Offer.
For more information, please contact:
Jesper Høiland, Chairman of the board, phone +45 612 207 30
Michael Colérus, CFO, phone +46 70 341 34 72
Certified Advisor (CA):
DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]
About SciBase:
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
Important information:
The publication, release or distribution of this press release in certain jurisdictions may be restricted by law and persons in the jurisdictions in which this press release has been published or distributed should inform themselves about and observe any such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction.
The availability of the Rights Issue, the TO 2 Offer and the Set-off Issue to holders who are not resident in Sweden may be affected by the laws of the relevant jurisdiction in which they are located. Holders who are not resident in Sweden should inform themselves about and observe any applicable legal and regulatory requirements.
This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in SciBase in any jurisdiction, neither from SciBase nor from anyone else. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue, the TO 2 Offer or the Set-off Issue. The Company has prepared and published information documents in the form prescribed in Annex IX to the Prospectus Regulation regarding the Rights Issue and the TO 2 Offer. The information documents are available on the Company's website (https://investors.scibase.se).
This press release does not identify or purport to identify any risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this press release is for the purpose of describing the background to the Rights Issue, the TO 2 Offer and the Set-off Issue, respectively, only and does not purport to be complete or exhaustive. No representation is made as to the accuracy or completeness of the information contained in this press release.
This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction where such announcement, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities legislation.
The Rights Issue, the TO 2 Offer and the Set-off Issue relate to securities in a non-US company and are subject to the disclosure requirements, rules and practices applicable to companies listed in Sweden, which differ from those of the United States in certain material respects. The Rights Issue, the TO 2 Offer and the Set-off Issue are not subject to the disclosure and other procedural requirements of Regulation 14D under the US Exchange Act of 1934, as amended (the "Exchange Act"). The Rights Issue, the TO 2 Offer and the Set-off Issue have been made solely to qualifying US holders in the United States in accordance with the requirements of Regulation 14E under the US Exchange Act to the extent applicable and subject to any exemptions or relief therefrom. Certain provisions of Regulation 14E under the Exchange Act are not applicable to the Rights Issue, the TO 2 Offer and the Set-off Issue by virtue of the Tier II exemptions provided by Rule 14d-1(d) under the Exchange Act.
The Company considers that it conducts activities worthy of protection under the FDI Act. In accordance with the FDI Act, the Company must inform prospective investors that the Company's activities may fall within the scope of the regulation and that the investment may be notifiable. In the event that an investment is notifiable, it must be notified to the ISP prior to its realization. An investment may be notifiable if (i) the investor, any member of its ownership structure or any person on whose behalf the investor is acting, after the investment is made, holds voting rights equal to or exceeding any of the thresholds of 10, 20, 30, 50, 65 or 90 percent of the total voting rights in the Company, (ii) the investor acquires the Company through the investment and the investor, any member of its ownership structure or any person on whose behalf the investor is acting, directly or indirectly, would hold 10 percent or more of the total voting rights in the Company; and (iii) the investor, any member of its ownership structure or any person on whose behalf the investor is acting, would acquire through the investment a direct or indirect influence in the management of the Company. An administrative fine may be imposed on the investor if a notifiable investment is made before the ISP has either (i) resolved to leave the notification without action or (ii) approved the investment. Each shareholder should consult an independent legal advisor regarding the possible application of the FDI Act in relation to the Rights Issue, the TO 2 Offer and the Set-off Issue for the individual shareholder.
Forward-looking statements
Matters discussed in this press release may contain forward-looking statements. Forward-looking statements are all statements that do not refer to historical facts and events, as well as statements that refer to the future and for example contain expressions such as "anticipates", "intends", "may', "will", "should", "estimates", "believes", "may", "plans", "continues", "potential", "estimates", "forecasts", "known" or similar expressions. In particular, these statements relate to future results of operations, financial condition, cash flows, plans and expectations of the Company's business and management, future growth and profitability and the general economic and regulatory environment and other circumstances affecting the Company, many of which are in turn based on additional assumptions, such as the absence of changes in existing political, legal, tax, market or economic conditions or in applicable laws (including, but not limited to, accounting principles, accounting methods and tax policies), which individually or in the aggregate could be material to the Company's results of operations or its ability to operate its business. Although the Company believes that these assumptions were reasonable when made, they are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and may be beyond the Company's control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements. Accordingly, prospective investors should not place undue reliance on the forward-looking information contained herein, and prospective investors are strongly advised to read those parts of the information documents that include a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The information, opinions and forward-looking statements contained in this press release are valid only as of the date of this press release and are subject to change without notice.
The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has resolved to postpone the publication of the year-end report for the financial year 2025 to March 13, 2026. The reason for the postponement is to align the trading restriction period with the ongoing rights issue, the subscription period of which ends today, January 26, 2026.
For more information, please contact:
Jesper Høiland, Chairman of the Board, phone +45 612 207 30
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases.
